To treat stomach and esophageal problems
  • Lansoprazole belongs to a class of antisecretory compounds,that do not exhibit anticholinergic or histamin H2-receptor antagonist properties ,but that suppress gastric acid secretion that acts by specific inhibition of the H+/K+-ATPase enzyme system.
  • Lansoprazole may be useful in patients failing on a histamine H2-receptor antagonist (Cimetidine,Ranitidine, Famotidine or Nizatidine).
  • Absorption of lansoprazole begins only after the pellets leave the stomach. Absorption is rapid, with peak plasma concentrations achieved about 1.5 hours after a dose by mouth; bioavailability is reported to be 80% or more even with the first dose.
  • lansoprazole is extensively metabolized in the liver and excreted primarily in faces via  bile,only about 15 to 30% of a dose is excreted in urine the plasma elimination half-life is around 1.4 to 2 hours but the duration of action is much longer.

Each capsule of LANTAK® 30 contains:

  • Lansoprazole (as enteric coated pellets)    30 mg.

Each capsule of LANTAK® 15 contains: 

  • Lansoprazole (as enteric coated pellets)    15 mg.

LANTAK® is indicated in the treatment of: 

  • Gastro-oesophageal reflux disease.
  • Peptic ulcer disease (duodenal and gastric ulcers).
  • Zollinger-Ellison syndrome.
  • Erosive Esophagitis.
  • Acid related dyspepsia.
  • Hypersensitivity to lansoprazole.
  • Antacids and sucralfate may reduce the bioavailability of LANTAK®, and should not be taken within 1 hour of a dose of LANTAK®
  • Lansoprazole is thought to be a weak inducer of hepatic cytochrome P450, and may affect the pharmacokinetics of the drugs which are metabolized by this system.
  • LANTAK® may interferes with the absorption of drugs where gastric pH is important determinant of bioavailability, (e.g. Ketoconazole, Iron salts, Ampicillin esters, and Digoxin).
  • LANTAK® should not be administered during pregnancy and lactation unless strictly indicated according to the physician recommendations.
  • LANTAK® has been well tolerated in both short-term and long-term treatment.
  • The most commonly reported possibly or probably treatment-related a dverse event during maintenance therapy was diarrhea.
  • It is normally taken before food in the morning.

Gastro-oesophageal reflux disease:

  • 30 mg daily by mouth for 4–8 weeks; thereafter maintenance therapy can be continued with 15 or 30 mg daily according to response.

Peptic ulcer disease:

  • 30 mg once daily. Treatment is continued for 4 weeks for duodenal ulcer and 8 weeks for gastric ulcer.
  • 15 mg daily has also been recommended as maintenance therapy for the prevention of relapse of duodenal ulcer.

Zollinger-Ellison syndrome:

  • the initial dose is 60 mg daily, adjusted as required. Doses of up to 90 mg twice daily have been used.

Erosive Esophagitis:

  • 30 mg once daily for up to 8 weeks.

In triple therapy regimens for elimination of Helicobacter pylori in peptic ulcer disease:

  • effective regimens include LANTAK® 30 mg twice daily combined with Clarithromycin 250 mg twice daily and either Amoxicillin 1g  twice  daily  or Metronidazole 400 mg twice daily; LANTAK®, Amoxicillin, and Metronidazole has also been used.

In patients with NSAID-associated ulceration:

  • a dose of 15 or 30 mg daily for 4–8 weeks is recommended.

For the relief of acid-related dyspepsia:

  • LANTAK® may be given in doses of 15 or 30 mg daily for 2–4 weeks.

Or as directed by the physician. 

  • Symptomatic response to therapy with LANTAK® does not preclude the presence of gastric malignancy. 
  • Dosage should be reduced in hepatic impairment.
  • LANTAK® Plastic jar of 14 capsules with a desiccant.
  • LANTAK® Pack  of 10 strips each strips containe 10 capsules.
  • Store in a dry place below 30 °C, protected from light and humidity.